CCM
INFI

Cadence Capital Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Cadence Capital Management’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-43,650
Closed -$737K – 656
2014
Q4 		$737K Buy
+43,650
New +$636K 0.04% 456
2013
Q4 		– Sell
-21,101
Closed -$368K – 663
2013
Q3 		$368K Sell
21,101
-4,329
-17% -$82.9K 0.01% 561
2013
Q2 		$412K Buy
+25,430
New +$787K 0.02% 360

Other funds holding INFI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cadence Capital Management's INFI Position: Q1 2015 in Review

Cadence Capital Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2015, closing a stake of 43,650 shares — an estimated $737K sold.

Cadence Capital Management first reported a position in INFI in Q2 2013 and held it in 3 quarters. The position peaked at $737K in Q4 2014. 141 funds tracked by Wall St. Rank hold INFI as of Q1 2015.

  • Cadence Capital Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Cadence Capital Management sold 43,650 Infinity Pharmaceuticals, Inc. shares in Q1 2015, an estimated $737K.
  • Cadence Capital Management first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 3 quarters.
  • Cadence Capital Management's Infinity Pharmaceuticals, Inc. position peaked at $737K in Q4 2014.
  • 141 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2015.

Based on Cadence Capital Management's 13F filing for Q1 2015, filed 30 Apr 2015.